Navigation Links
Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
Date:9/30/2013

that tumor-cell associated HA may be a better predictor of PEGPH20 combination treatment effect compared to stromal associated HA.

Treatment was generally well tolerated, and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. The most common adverse events for PEGPH20 were muscle spasms, myalgia and arthralgia (all grade 1/2). There was no evidence of new toxicities when used in combination with gemcitabine and the pharmacokinetics of PEGPH20 with gemcitabine was consistent with the pharmacokinetics of PEGPH20 as a single agent. Additionally, the pharmacodynamic and pharmacokinetics results support the dosing regimen of PEGPH20 at 3µg/kg, which is being used in an on-going Phase 2 trial.

Halozyme has initiated a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 in combination with nab-paclitaxel and gemcitabine to confirm the combination treatment effect (ORR, PFS and OS) based on HA levels. The study plans to enroll approximately 124 patients with stage IV pancreatic ductal adenocarcinoma. Halozyme is also developing an HA diagnostic tool to be used in this study to evaluate the potential treatment benefit based on tumor HA levels at baseline. This diagnostic approach may enable additional PEGPH20 combination clinical studies in other HA-rich tumor types.

About PEGPH20

Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is itself an indicator of poor prognosis. PEGPH20 has been shown to deplete this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render the tumor more vulnerable to therapy as well as inhibit tumor growth.

About Pancreatic Cancer

In most patients diagnosed with metastatic pancreatic adenocarcinoma, survival rates are the low
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
2. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
3. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
4. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
5. Halozyme Reports Second Quarter 2013 Financial Results
6. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
7. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
8. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
9. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
10. Halozyme Reports First Quarter 2013 Financial Results
11. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... W.Va. , July 23, 2014 /PRNewswire-iReach/ -- The ... a new five-state Quality Innovation Network-Quality Improvement Organization (QIN-QIO) ... Medical Institute (WVMI). Effective August 1, WVMI ... West Virginia , Pennsylvania ... Jersey and Louisiana.  The Network will engage ...
(Date:7/23/2014)... 23, 2014 Creekridge Capital, an independent ... new vendors so far in 2014 to their ... vendors are from both the healthcare and technology ... large, well-known multi-national companies. Each of these new ... financing products including: standard leasing products, subscription solutions, ...
(Date:7/23/2014)... 2014  When it comes to welcoming our new robot ... roll out the red carpet. Healthcare is one ... 9000-like robots into our human sphere. With healthcare concerns top ... need to apply new technologies to help with old problems. ... robotics is expected to increase from $1.7 billion now to ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2Creekridge Capital Signs Several New Vendor Partners 2
... Aug. 26 The Oregon Tourism Commission,launched its ... Program,(Q Care) this week on http://www.OregonQCare.com ., ... created to support the tourism and,hospitality industry through ... customer service, the training will equip,employees with tools ...
... Semafore Pharmaceuticals Inc.,announced data presented at the ... Washington, D.C., showing additional antiangiogenic,activity of vascular-targeted PI3 ... Bv8 signaling., PI3K is part of a ... been shown to play a major role in ...
Cached Medicine Technology:Oregon Tourism Commission Unveils New Online Customer Service Training Program 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3
(Date:7/23/2014)... VA (PRWEB) July 23, 2014 Inventor ... America: From football games to the gas pump – ... guests on Wednesday, July 30 at Noon. , With ... Legislator has more patents than anyone in the General ... football’s superimposed yellow line yard marker as seen on ...
(Date:7/23/2014)... The National Institute of Biomedical Imaging and Bioengineering ... Symposium on July 30, 2014 on the NIH campus. ... investigators covering a wide breadth of NIBIB-funded research. ... Cohen, Harvard, Engineering Microbial Rhodopsins as Optical Voltage Sensor, ... Fluorescently Labeled Probes for Nerve Imaging ...
(Date:7/23/2014)... Bodybuilding.com, the Internet’s most-visited bodybuilding and fitness ... has officially opened the polls for their tenth annual ... growing sports nutrition company, is up for eight awards ... Best Tasting Protein of the Year- Whey-HD™, Most Innovative ... - Whey-HD™, Pre-workout Supplement of the Year - 1.M.R ...
(Date:7/23/2014)... 23, 2014 Olympic gold medal-winning speed ... Virginia on Friday, July 18. Hedrick visited Roanoke as ... Commonwealth Games, an Olympic-style event celebrating its 25th Anniversary ... as a premier sponsor of the Commonwealth Games, which ... all ages and all activity levels. , Hedrick, a ...
(Date:7/23/2014)... effort to catalog the molecular causes of stomach ... have identified four subtypes of tumors based on ... the new classification promises to advance clinical research ... killer worldwide. , In a report in ... Research Network said they analyzed 295 samples of ...
Breaking Medicine News(10 mins):Health News:Celebrating Innovation and Invention 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3
... had a piercing somewhere other than their ear lobe, with ... in a hospital admission, according to a study published on ... public health doctors from the Health Protection Agency and the ... women are three times more likely than men to have ...
... Key, WASHINGTON, June 13 A team ... to Germany on Saturday,to work with the US ... current rehabilitation practices. They will also make,recommendations for ... to,injured soldiers and other military personnel in need ...
... findings suggest men fighting over women took place even in ... fighting over women? Nothing new there, based on the findings ... Durham University-led researchers say that genetic evidence from 34 skeletons ... the result of a tribal war over the need for ...
... The Blinded,American Veterans Foundation (BAVF), at its June ... Delegate Sheila Hixson., "We,re honored to recognize Delegate ... District 20 and to the entire State of,Maryland," said ... efforts as a legislator and community activist are known,throughout ...
... Leading Cause of Work Disability in Europe, ... that treating patients with early, active rheumatoid arthritis ... in an,indirect cost savings of euro 4,845 (or ... the study) per patient per year compared to,MTX ...
... Effort to Find Cure, WASHINGTON, June 12 ... died in 2005 of peritoneal,mesothelioma, will be a ... June 27th, part of the Mesothelioma Applied Research ... 26th through Saturday, June 28th at the Hyatt ...
Cached Medicine News:Health News:1 in 10 adults has a non-earlobe piercing 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 4Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 5Health News:Pursuit of Females Dates Way, Way Back 2Health News:Blinded Vets Foundation to Honor Maryland State Delegate Sheila Hixson 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 3Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 4Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 5Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 6Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 7Health News:Asbestos Tragedy and Hope 2
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The uncemented hip joint prosthesis system....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: